Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
:BHVN
BHVN Analyst Ratings
Moderate Buy
7 Buy
6 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BHVN Stock 12 Month Forecast
Average Price Target
$15.09
▲(30.88% Upside)
| Highest Price Target$30.00 | Average Price Target$15.09 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
$30
Buy
160.19%
Upside
Reiterated
12/05/25
H.C. Wainwright
$30→$11
Hold
-4.60%
Downside
Downgraded
12/03/25
UBS
$26→$11
Hold
-4.60%
Downside
Downgraded
11/28/25
J.P. Morgan
$47→$15
Buy
30.10%
Upside
Reiterated
11/19/25
Morgan Stanley
$54→$26
Buy
125.50%
Upside
Reiterated
11/17/25
Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory ChallengesWe have lowered our near-term opex assumptions, primarily on the R&D side, by ~$200–$300mn while keeping outer-year estimates largely unchanged; for reference, FY2024 opex (R&D + SG&A, excluding non-cash SBC) was $885mn. The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2 data in major depressive disorder (MDD), which is expected in 4Q25- see our preview HERE, and two Ph2/3 studies in focal epilepsy with initial topline results expected in 1H26. We previously noted that Xenon's (not covered) azetukalner (XEN1101; Ltd (BHVN.N) Ltd | North America Refreshing model for Troriluzole CRL and 3Q; Opakalim MDD data up next Troriluzole received a CRL for SCA, and BHVN plans to cut R&D spend by ~60%. We remove Troriluzole and update our model following 3Q results.
BTIG
$16
Buy
38.77%
Upside
Reiterated
11/17/25
Citi
$28→$14
Buy
21.42%
Upside
Reiterated
11/12/25
RBC Capital
$9
Hold
-21.94%
Downside
Reiterated
11/10/25
William Blair
―
Hold
―
Downgraded
11/10/25
Bank of America Securities
$10
Hold
-13.27%
Downside
Reiterated
11/10/25
TD Cowen
$15
Buy
30.10%
Upside
Reiterated
11/10/25
Strategic Pipeline Focus and Cost Management Drive Buy Rating for Biohaven Ltd.We expect that R&D expenses will get cut in half to preserve runway for these programs. A Type A meeting with the FDA has been requested to appeal the tror/SCA CRL, but investors should consider this program to be in the rear-view mirror.
Bernstein
$34→$9
Hold
-21.94%
Downside
Downgraded
11/06/25
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical OutcomesWe are downgrading BHVN to $9 PT following Tuesday’s announcement of the CRL for troriluzole in SCA - see our initial reaction here. This is a painful downgrade, as we remain excited about the LT value of the degrader platform, the original reason for our Outperform rating.
Raymond James
―
Buy
―
Reiterated
11/03/25
Optimistic Buy Rating for Biohaven Ltd. Amidst High-Risk PDUFA Decision on TroriluzoleWe think investors would do well to understand some key differences. First, with turmoil at FDA top of mind, we highlight that it is CDER’s Neurology I division reviewing BHVN’s application and CBER interacting with QURE. While the centers do share expertise, there are different patterns for each center. Other differences include the fact that QURE has not yet filed, while BHVN has filed, FDA accepted the file, and assigned priority review. Finally, we note that QURE’s program (gene therapy requiring brain surgery for delivery) is quite a different proposition than an oral prodrug of riluzole (a long-approved treatment for ALS) with a benign safety profile.
Leerink Partners
$60→$50
Buy
333.65%
Upside
Reiterated
08/12/25
Robert W. Baird
$57→$52
Buy
351.00%
Upside
Reiterated
08/12/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
$30
Buy
160.19%
Upside
Reiterated
12/05/25
H.C. Wainwright
$30→$11
Hold
-4.60%
Downside
Downgraded
12/03/25
UBS
$26→$11
Hold
-4.60%
Downside
Downgraded
11/28/25
J.P. Morgan
$47→$15
Buy
30.10%
Upside
Reiterated
11/19/25
Morgan Stanley
$54→$26
Buy
125.50%
Upside
Reiterated
11/17/25
Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory ChallengesWe have lowered our near-term opex assumptions, primarily on the R&D side, by ~$200–$300mn while keeping outer-year estimates largely unchanged; for reference, FY2024 opex (R&D + SG&A, excluding non-cash SBC) was $885mn. The next catalyst for the stock is Opakalim (BHV-7000; Kv7 activator) Ph2 data in major depressive disorder (MDD), which is expected in 4Q25- see our preview HERE, and two Ph2/3 studies in focal epilepsy with initial topline results expected in 1H26. We previously noted that Xenon's (not covered) azetukalner (XEN1101; Ltd (BHVN.N) Ltd | North America Refreshing model for Troriluzole CRL and 3Q; Opakalim MDD data up next Troriluzole received a CRL for SCA, and BHVN plans to cut R&D spend by ~60%. We remove Troriluzole and update our model following 3Q results.
BTIG
$16
Buy
38.77%
Upside
Reiterated
11/17/25
Citi
$28→$14
Buy
21.42%
Upside
Reiterated
11/12/25
RBC Capital
$9
Hold
-21.94%
Downside
Reiterated
11/10/25
William Blair
―
Hold
―
Downgraded
11/10/25
Bank of America Securities
$10
Hold
-13.27%
Downside
Reiterated
11/10/25
TD Cowen
$15
Buy
30.10%
Upside
Reiterated
11/10/25
Strategic Pipeline Focus and Cost Management Drive Buy Rating for Biohaven Ltd.We expect that R&D expenses will get cut in half to preserve runway for these programs. A Type A meeting with the FDA has been requested to appeal the tror/SCA CRL, but investors should consider this program to be in the rear-view mirror.
Bernstein
$34→$9
Hold
-21.94%
Downside
Downgraded
11/06/25
Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical OutcomesWe are downgrading BHVN to $9 PT following Tuesday’s announcement of the CRL for troriluzole in SCA - see our initial reaction here. This is a painful downgrade, as we remain excited about the LT value of the degrader platform, the original reason for our Outperform rating.
Raymond James
―
Buy
―
Reiterated
11/03/25
Optimistic Buy Rating for Biohaven Ltd. Amidst High-Risk PDUFA Decision on TroriluzoleWe think investors would do well to understand some key differences. First, with turmoil at FDA top of mind, we highlight that it is CDER’s Neurology I division reviewing BHVN’s application and CBER interacting with QURE. While the centers do share expertise, there are different patterns for each center. Other differences include the fact that QURE has not yet filed, while BHVN has filed, FDA accepted the file, and assigned priority review. Finally, we note that QURE’s program (gene therapy requiring brain surgery for delivery) is quite a different proposition than an oral prodrug of riluzole (a long-approved treatment for ALS) with a benign safety profile.
Leerink Partners
$60→$50
Buy
333.65%
Upside
Reiterated
08/12/25
Robert W. Baird
$57→$52
Buy
351.00%
Upside
Reiterated
08/12/25
Best Analysts Covering Biohaven Ltd.
1 Month
xxx
Success Rate
7/11 ratings generated profit
Average Return
+4.75%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +4.75% per trade.
3 Months
xxx
Success Rate
6/13 ratings generated profit
Average Return
-0.92%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of -0.92% per trade.
1 Year
Success Rate
10/22 ratings generated profit
Average Return
+20.52%
reiterated a buy rating 27 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +20.52% per trade.
2 Years
xxx
Success Rate
5/22 ratings generated profit
Average Return
-25.41%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.73% of your transactions generating a profit, with an average return of -25.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BHVN Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
12
14
16
18
16
Buy
3
3
2
1
1
Hold
1
2
2
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
19
20
27
25
Each month's total comprises the sum of three months' worth of ratings.
BHVN Financial Forecast
BHVN Stock Forecast FAQ
What is BHVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 15.09.
What is BHVN’s upside potential, based on the analysts’ average price target?
Biohaven Ltd. has 30.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BHVN a Buy, Sell or Hold?
Biohaven Ltd. has a consensus rating of Moderate Buy which is based on 7 buy ratings, 6 hold ratings and 0 sell ratings.
What is Biohaven Ltd.’s price target?
The average price target for Biohaven Ltd. is 15.09. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $9.00. The average price target represents 30.88% Increase from the current price of $11.53.
The highest analyst price target is $30.00 ,the lowest forecast is $9.00. The average price target represents 30.88% Increase from the current price of $11.53.
What do analysts say about Biohaven Ltd.?
Biohaven Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of BHVN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.